KALA BIO Secures Convertible Loan Amid Default and 27% Stock Surge

Introduction

KALA BIO INC (Nasdaq: KALA), founded in 2009 and headquartered in Arlington, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing biologics for rare and severe ophthalmic diseases. Utilizing its proprietary mesenchymal stem cell secretome (MSC-S) platform, KALA BIO is advancing a pipeline of therapies aimed at preserving and restoring vision in conditions with limited or no approved treatments.

Corporate Structure and Leadership

KALA BIO has between 2 and 10 employees, as indicated in its LinkedIn profile. The company is led by a team with experience in ophthalmology and biopharmaceutical development:

• Mark Iwicki, Chair and Chief Executive Officer, has over 25 years of experience in R&D and commercialization in the industry.
• Todd Bazemore, Interim CEO (Feb–Sep 2025) and former COO, brings more than 30 years of experience in orphan and primary-care markets.
• Dr. Thomas Brazzell, Chief Medical Officer since February 2013, has extensive clinical research experience in ophthalmic therapeutics.
• Darius Kharabi, Chief Business Officer since November 2021, was a co-founder of Combangio Inc. and has experience in stem cell and secretome ventures.
• Susan Reumuth, Chief Financial Officer since July 2017, has a finance background with roles at Genzyme, Enobia, and other biotech firms.

Ophthalmic Biologics by Pawel Czerwinski

Recent Developments and News

On August 2, 2023, Kala Pharmaceuticals officially changed its name to KALA BIO to reflect its focus on biologics. The company’s lead candidate, KPI-012, received Orphan Drug and Fast Track designations from the FDA for the treatment of persistent corneal epithelial defect (PCED) and is currently undergoing a Phase 2b CHASE trial. A webcast featuring industry experts on KPI-012's potential took place on July 16, 2025.

In late September 2025, Oxford Finance LLC declared an event of default on KALA BIO’s loan agreement and indicated intentions to foreclose on company assets. Consequently, KALA BIO reduced its workforce significantly, retaining only essential personnel for asset preservation. On November 9, 2025, the company entered into a Convertible Loan Agreement for up to $375,000 to assist in preparing and filing its delayed Form 10-Q. The notification of inability to timely file (NT 10-Q) was submitted on November 14, 2025, with the quarter-end report following on November 19, 2025. An 8-K current report covering several items was filed on November 25, 2025.

Financial and Strategic Analysis

As of December 1, 2025, KALA BIO’s stock closed at $1.23, representing a 27.32% increase with a trading volume of 13,560,176 shares. The company is facing liquidity challenges following the September 29 notification of default. The convertible loan agreement is intended primarily for regulatory filings rather than R&D or commercialization efforts. KALA BIO's strategic focus is on progressing KPI-012 through Phase 2b endpoints to support a Biologics License Application and on the preclinical development of KPI-014 for inherited retinal degenerations. The results of the CHASE trial and ongoing negotiations with its lender will be important factors in determining future operations.

Market Position and Industry Context

KALA BIO operates in the arena of rare ophthalmic diseases, where there is a significant unmet medical need and market entry barriers include regulatory designations and the complexity of biologic manufacturing. Its MSC-S platform offers a cell-free alternative to stem cell therapies, applicable to both front- and back-of-the-eye conditions. KPI-012 aims to be the first broadly indicated treatment for PCED, while KPI-014 anticipates providing a gene-agnostic approach for inherited retinal diseases, an area currently served by gene-specific therapies. The competitive landscape includes established ophthalmic product developers and emerging therapies in both gene and cell-based categories.

tl;dr

On December 1, 2025, KALA BIO’s stock increased by 27.32% to $1.23 amid substantial trading volume. The company continues its Phase 2b CHASE trial of KPI-012 for PCED and is evaluating KPI-014 in preclinical retinal programs. Following a September 29 notification of default from Oxford Finance LLC, KALA BIO secured up to $375,000 through a November 9 convertible loan to facilitate delayed SEC filings (NT 10-Q filed on November 14; Form 10-Q submitted on November 19) and filed an 8-K on November 25. The future outlook will depend on results from the CHASE trial and negotiations with its lender to stabilize liquidity.